April 24th 2024
In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Clarity Pharmaceuticals to Begin Phase 3 Trial for New PSMA PET Agent for Prostate Cancer
July 5th 2023The prospective multicenter trial, which is slated to begin patient recruitment in late 2023, will reportedly assess the ability of 64Cu SAR-bisPSMA to diagnose prostate cancer within pelvic lymph nodes.
Deep Learning Network Shows Significant Potential for Prostate Cancer Detection on MRI
June 22nd 2023In multiple datasets from a study involving reviewed data from over 2,700 bi-parametric magnetic resonance imaging (MRI) scans, a deep neural network demonstrated area under the receiver operating characteristic (AUROC) scores ranging from 87 to 89 percent for the detection of clinically significant prostate cancer.
Study Says AI Mapping More Effective than MRI for Assessing Extent of Prostate Cancer
June 15th 2023Combining multimodal imaging data and biopsy data, an artificial intelligence (AI) model provided enhanced sensitivity for defining prostate cancer tumor margins in comparison to conventional magnetic resonance imaging (MRI) assessments.
PSMA PET Imaging May Offer Key Prognostic Markers for Prostate Cancer
June 12th 2023For patients initially diagnosed with non-metastatic, castration-resistant prostate cancer, pelvic lymph node involvement and five or more polymetastases detected with prostate-specific membrane antigen (PSMA)/ positron emission tomography (PET) are significantly associated with lower overall survival rates, according to recently presented research at the American Society of Clinical Oncology (ASCO) conference.
FDA Approves New PSMA PET Agent POSLUMA for Prostate Cancer Imaging
May 30th 2023Reportedly the first FDA-approved PSMA PET agent with proprietary radiohybrid technology, POSLUMA can be utilized for positron emission tomography (PET) scans of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer and suspected metastasis, and those with suspected prostate cancer recurrence based on an elevated serum prostate-specific antigen (PSA) level.
Study Shows Benefits of AI for Prostate Cancer Detection on Multiparametric MRI
May 3rd 2023The use of adjunctive artificial intelligence (AI) reportedly improved lesion level sensitivity by nearly 19 percent and patient level specificity by 14 percent for the diagnosis of clinically significant prostate cancer on multiparametric magnetic resonance imaging (MRI).
FDA Clears RadNet's Updated AI Software for Prostate MRI
May 1st 2023An update to Quantib Prostate 2.1, Quantib Prostate 3.0 reportedly facilitates workflow advances and offers a variety of tools, ranging from artificial intelligence (AI)-based segmentation to PI-RADS scoring support, to help improve interpretation of prostate magnetic resonance imaging (MRI).
Emerging Prostate and Brain MRI AI Platform Gets FDA Nod
April 13th 2023In addition to a previously FDA-cleared brain magnetic resonance imaging (MRI) module, the Advantis Platform features an artificial intelligence-powered prostate MRI module that offers simultaneous viewing of conventional and advanced sequences, and reportedly generates automated PI-RADS assessments.
Can Explainable AI Enhance Diagnosis and PI-RADS Classification of Prostate Cancer on MRI?
April 12th 2023In a study of over 1,200 men with over 3,200 prostatic lesions, an explainable artificial intelligence (AI) model demonstrated a sensitivity rate of 93 percent for detecting clinically significant prostate cancer.
Study Finds No Impact for Deep Learning Software in PI-RADS Scoring or Diagnosis of Prostate Cancer
March 28th 2023In a recent study of a deep learning software in patients with suspected prostate cancer, researchers noted no difference in the detection of clinically significant prostate cancer nor PI-RADS scoring consistency.
Cancer Screenings and COVID-19: What a New Study Shows
February 27th 2023New research from the American Cancer Society comparing pre-pandemic cancer screening prevalence to the second year of the COVID-19 pandemic in the United States showed a 1.1 million decrease in breast cancer screenings, a 4.4 million decrease in cervical cancer screening and a 600,000 decrease in prostate cancer screenings.
Recurrent Prostate Cancer and Low PSA Levels: Can an Emerging PSMA PET Agent Have an Impact?
February 16th 2023Use of the prostate-specific membrane antigen (PSMA) positron emission tomography (PET) agent piflufolastat F 18 led to treatment plan changes in nearly 40 percent of men with recurrent prostate cancer and low prostate-specific antigen (PSA) levels, according to new research presented recently at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers (GU) Symposium in San Francisco.
Should Vertebral Fracture Assessment be Standard Prior to ADT Treatment for Prostate Cancer?
January 10th 2023A new study found that approximately one-third of men with prostate cancer were diagnosed with at least one vertebral fracture prior to the initiation of androgen deprivation therapy (ADT).